
The Commercialization of Biomarkers: Opportunities and Challenges Ahead
Healthcare | Jun, 2026
For years, biomarkers were discussed primarily in research settings, conference halls, and laboratory pipelines. Today, that has changed. Biomarkers are no longer viewed only as scientific signals; they are increasingly being treated as commercial assets that can shape diagnostics, drug development, patient stratification, disease monitoring, and even digital care models.
Read More